MMI Achieves Major Milestones with FDA Clearance for Robotic Microsurgical Instruments and New CPT Reimbursement Code
核心洞察
Medical Microinstruments (搜索) (MMI (搜索)) received FDA 510(k) clearance for NanoWrist Scissors and Forceps, enabling the world's first fully robotic-assisted microsurgical operation from incision to closure.
The American Medical Association issued a new CPT code (1019T) for lymphovenous bypass surgery, with CMS finalizing payment rates effective January 1, 2026.
Tampa General Hospital completed the first U.S. clinical use of the cleared dissection instruments in a lymphovenous bypass procedure for lymphedema treatment.
Medical Microinstruments (搜索) (MMI (搜索)) has achieved two significant regulatory milestones that could transform the landscape of microsurgical treatment for lymphedema patients. The company received FDA 510(k) clearance for its NanoWrist Scissors and Forceps for soft tissue dissection, while simultaneously securing a new CPT code and CMS reimbursement for robotic lymphatic surgery procedures.
FDA Clearance Enables Fully Robotic Microsurgery
The FDA clearance for MMI (搜索)'s NanoWrist Scissors and Forceps represents a breakthrough in robotic microsurgical capabilities. These instruments, designed specifically for dissection in open microsurgery, are the world's first and smallest fully wristed robotic instruments for this application. The clearance expands the role of MMI's Symani Surgical System beyond anastomosis to include critical tissue manipulation and dissection steps.
Tampa General Hospital recently completed the first U.S. clinical use of the cleared instruments in a lymphovenous bypass (LVB) procedure, marking what the company describes as the world's first fully robotic-assisted microsurgical operation from initial incision to skin closure.
Dr. Nicholas J. Panetta, Chair of the Department of Plastic Surgery at the University of South Florida Morsani College of Medicine and Chief of the Plastic Surgery Institute at Tampa General Hospital, performed the procedure using the complete NanoWrist Instrument Portfolio. "Robotics will define the future of microsurgery, especially in lymphedema work where sub-millimeter precision is essential," Dr. Panetta stated. "With robotic enabled dissection, I was able to complete a fully robotic LVB, from incision to closure, with unmatched precision, control and improved ergonomics."
New CPT Code Addresses Reimbursement Barriers
In parallel with the FDA clearance, the American Medical Association issued a new Category III CPT code (1019T) for lymphovenous bypass procedures, including robotic assistance. The Centers for Medicare & Medicaid Services also finalized payment rates for LVB procedures performed in outpatient settings, to be reflected in the CY 2026 OPPS Final Rule. The new code becomes effective January 1, 2026.
Previously, lymphovenous bypass procedures required billing under unlisted surgical codes, creating reimbursement challenges that limited adoption. The new CPT code is designed to capture both manual and robotic-assisted lymphovenous bypass surgeries while enabling procedure data collection to advance reimbursement pathways.
"This development marks a major step forward in making surgical treatment for lymphedema more widely available," said Mark Toland, CEO of MMI (搜索). "This code not only validates the importance and complexity of lymphatic surgery but also lays the groundwork for expanding patient access, advancing reimbursement policy, and driving broader adoption of innovative surgical techniques across the U.S."
Addressing Significant Unmet Medical Need
Lymphedema affects more than 250 million people worldwide, with most patients relying on lifelong symptom management including massage, compression garments, and manual drainage. While surgical options like LVB offer potential for lasting relief, adoption has been constrained by procedural complexity and the limited number of surgeons capable of performing supermicrosurgical techniques on delicate vessels.
The Symani Surgical System addresses these technical barriers by providing precision and control needed to perform LVB procedures consistently. The system allows surgeons to connect tiny lymphatic vessels—smaller than several strands of hair—to nearby veins, helping reroute fluid and relieve swelling. Early studies have shown encouraging results, including reduced limb volume, decreased reliance on compression garments, and improved quality of life for patients.
William Repicci, President & CEO of the Lymphatic Education & Research Network, emphasized the significance of these developments: "For the first time, hospitals will be able to sustainably offer a microsurgical treatment that restores lymphatic flow and profoundly improves quality of life. This milestone validates years of scientific progress and advocacy to ensure that lymphatic surgery receives the recognition—and reimbursement—it deserves."
Technical Specifications and Capabilities
The NanoWrist Scissors and Forceps offer seven degrees of freedom, delivering precise robotic capabilities with Symani's motion scaling and tremor reduction features. These instruments are designed to preserve tissue integrity and reduce vessel trauma, which is critical in complex procedures such as surgical lymphatic repair, perforator-to-perforator reconstruction, and cancer-related head and neck reconstruction.
The complete NanoWrist Instrument Portfolio includes the newly cleared Scissors and Forceps, along with the previously available SuperMicro Needle Holder Suture Cut and SuperMicro Dilator. All instruments work within the Symani platform, which combines the world's smallest wristed microinstruments with tremor-reducing and motion-scaling technologies.
Market Impact and Future Implications
These regulatory achievements remove two significant barriers to broader microsurgical adoption: technical feasibility and economic viability. The combination of robotic precision and established reimbursement pathways creates opportunities for hospitals to offer advanced surgical options for patients, strengthen existing lymphatic programs, and develop new programs focused on procedural growth and enhanced patient outcomes.
The developments follow other significant milestones for MMI (搜索) in 2025, including advancement into neurosurgery, launch of the largest U.S. prospective clinical trial in robotic microsurgery, and expanded technological capabilities. The Symani Surgical System remains the only microsurgical robot approved for commercial use and is FDA-cleared in the U.S. and CE Marked in Europe.